ADRO stock forecast
Our latest prediction for Aduro BioTech, Inc.'s stock price was made on the Sept. 15, 2020 when the stock price was at 2.41$.
In the short term (2weeks), ADRO's stock price should outperform the market by 0.65%. During that period the price should oscillate between -10.59% and +14.39%.
In the medium term (3months), ADRO's stock price should underperform the market by -6.00%. During that period the price should oscillate between -41.98% and +35.98%.Get email alerts
Create a solid portfolio with ADRO
About Aduro BioTech, Inc.
Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.
At the moment the company generates 28M USD in revenues.
On its last earning announcement, the company reported a loss of -0.80$ per share.
The book value per share is 2.23$
Three months stock forecastSept. 15, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|